Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta DrugsNSE:BETA -5.76%96 Net Margin % is 12.59% as of Jun. 2026, which is 5% above its 10-year median of 11.95. GuruFocus rates NSE:BETA with a GF Score™ of 96/100 and a GF Value™ of ₹2,681.82 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Beta Drugs ranks better than 67.78% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Beta Drugs's Net Income for the
three
months ended in Jun. 2026 was ₹158 Mil. Beta Drugs's Revenue for the
three
months ended in Jun. 2026 was ₹1,255 Mil. Therefore, Beta Drugs's net margin for the quarter that ended in Jun. 2026 was 12.59%.
The historical rank and industry rank for Beta Drugs's Net Margin % or its related term are showing as below:
NSE:BETA'
s Net Margin % Range Over the Past 10 Years
Min: 10.1 Med: 11.95 Max: 13.53
Current: 11.11
NSE:BETA's Net Margin % is ranked better than 67.78% of 959
companies
in the Drug Manufacturers industry
Industry Median: 5.32
vs NSE:BETA: 11.11
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Beta Drugs Net Margin % Related Terms
Beta Drugs Net Margin % Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Net Margin % distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a Net Margin % of 12.59% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Beta Drugs and its competitors. This is near median its historical median of 11.95. Over the past decade, Beta Drugs' Net Margin % has ranged from 10.10 to 13.53. According to the industry distribution chart, Beta Drugs ranks #309 out of 959 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is Beta Drugs' Net Margin % too high?
Beta Drugs' current Net Margin % of 12.59% is near median its 10-year median of 11.95. Over the past 10 years, this metric has ranged from a low of 10.10 to a high of 13.53. The Drug Manufacturers industry median Net Margin % is 5.32. Beta Drugs' value of 12.59% is 136.7% above this industry median. Based on the distribution chart, Beta Drugs ranks #309 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beta Drugs has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #309 out of 959 companies for Net Margin %. This puts Beta Drugs in the upper half of its industry. The industry median Net Margin % is 5.32. Beta Drugs' value of 12.59% is 136.7% above this benchmark. Historically, Beta Drugs' own Net Margin % has ranged from 10.10 to 13.53 over the past decade. While the company's 10-year median is 11.95 vs. the industry median of 5.32, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.32, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current Net Margin % of 12.59% is 136.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Net Margin % is 12.59%, which is near median its own 10-year median of 11.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,681.82, compared to a current price of ₹2,373.70 — trading 11.5% below its estimated fair value. The current Net Margin % is 12.59%, which is near median its 10-year median of 11.95 and 136.7% above the Drug Manufacturers industry median of 5.32. Beta Drugs' overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Net Margin % is 12.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be undervalued.
The current stock price of ₹2,373.70 is trading 11.5% below its estimated GF Value™ of ₹2,681.82.
GuruFocus considers Beta Drugs to be Modestly Undervalued.
Key valuation signals for NSE:BETA:
Net Margin %: 12.59% (near median its 10-year median of 11.95)
GF Value™: ₹2,681.82 vs. price of ₹2,373.70 (11.5% below fair value)
Industry Position: 136.7% above the Drug Manufacturers median (#309 of 959)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
96GF Score
Get the complete analysis for NSE:BETA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
